Sarah Garner work email
- Valid
- Valid
- Valid
- Valid
Sarah Garner personal email
Pharmacist specialising in multi-sector engagement to improve access to medicines and healthcare products. Sarah has 15 years experience working internationally and nationally with governments and stakeholders to develop policy and strategy. Sarah is currently the Senior Policy Advisor for the Access to Medicine and Healthcare Products Team at WHO EURO. Her previous roles have included Co-ordinator for Access to Medicines at WHO HQ, the Associate Director for Science Policy and Research at the UK's National Institute for Health and Care Excellence (NICE) and Pharmacist Lead for the UK Government’s Special Advisory Committee on Antimicrobial Resistance. Sarah is skilled at trouble-shooting, multi-stakeholder negotiation and collaboration. She is the lead for the WHO Access to Novel Medicines Platform and has previously led policy and research work-packages of major EU public-private research partnerships funded by the Innovative Medicines Initiative. Her research and policy experiences include new development mechanisms for medicines for unmet need, the use of digital information/ real-word data in pharmaceutical development, regulatory and HTA decision-making methodology and disinvestment (low-value care). Sarah has a PhD in Health Technology Assessment and is an honorary professor at UCL and Manchester Universities and a Harkness Fellow in Healthcare Policy and Practice.
University College London
View- Website:
- ucl.ac.uk/archaeology-south-east
- Employees:
- 73
-
Honorary ProfessorUniversity College LondonLondon, Gb
-
Senior Policy Advisor Who EuroWorld Health Organization Mar 2022 - Present -
Co-Ordinator 'Innovation, Access And Use' - Essential Medicines And Health Products.World Health Organization May 2017 - Mar 2022GenevaLeadership and management of the Innovation, Access and Use team of the WHO Essential Medicines and Health Products Department. The team provides leadership and support for the co-ordination and development of all aspects of the work of WHO that contribute to effective and efficient pharmaceutical and technology systems for Universal Health Coverage. This includes the Expert Committees on Selection and Use of Essential Medicines and Health Products, Expert Committee on Drug Dependence, work on national policies, procurement, supply management and pricing of health technologies (medicines, vaccines, diagnostics, devices and assistive technology. Public Health, Innovation and Intellectual property including financing and co-ordination of research and development for health technologies with focus on developing countries.
-
Honorary ProfessorUniversity College London Dec 2013 - PresentInstitute of Epidemiology and Public Health Care -
Honorary ProfessorThe University Of Manchester Jan 2015 - Present -
European Conference Co-Chair 2018 And Plenary ModeratorIspor—The Professional Society For Health Economics And Outcomes Research Jul 2018 - Oct 2018Barcelona Area, SpainIn 2017, the World Health Organization (WHO) convened the first Fair Pricing Forum to focus global attention on the apparent perversity of high prices that restrict access to essential patented medicines and the unpredictability of low prices that drive shortages in the generics sector. Stakeholders discussed perspectives on the current pricing systems and identified a need for a fairer system that is sustainable for health systems, investors, and the pharmaceutical industry. While the definition of what is fair and whether it is feasible to achieve are two separate but related constructs, the focus of the plenary is on defining “fair” in the context of pharmaceutical pricing. Speakers will also explore whether it is possible (or necessary) to come to a shared understanding of fairness. Could a renewed focus on the shared objectives of achieving universal health coverage, sustainable development goals, and access to medicines provide the catalyst for identifying non-regulatory strategiesto address the current inequities and provide much needed access? Or is further regulation required -
Associate Director Science Policy And ResearchNational Institute For Health And Care Excellence Aug 2008 - May 2017The Associate Director for Scientific Policy and Research is responsible for the planning and delivery of NICE’s R&D agenda relating to methodology and clinical research. Responsibilities include scientific policy development; liaison with national funding bodies and the research community; identification and promotion of clinical research recommendations; NICE’s Citizens Council; NICE’s Technical Forum and the Institute Research Advisory Group. -
Wp1 Co-LeadImi Getreal Project Oct 2013 - Apr 2017GetReal is a project of the Innovative Medicines Initiative (IMI), a public-private consortium consisting of pharmaceutical companies, academia, HTA agencies and regulators (e.g., NICE, HAS, EMA and CVZ), patient organisations and SMEs.The GetReal consortium aims to improve the efficiency of the medicine development process by better incorporating estimates of relative effectiveness into drug development and to enrich decision-making by regulatory authorities and HTA bodies.The overall aim of WP1 is to create a shared platform to address the inclusion of alternative study designs in drug development strategies. Such a platform is required to ensure that the identified options meet the needs of all relevant parties as a medicine transitions from its development stages through to use in the clinical setting, while also increasing the efficiency and/or reducing the cost of the research and development process. This should be achieved without compromising the robustness of the data for decision-making both from a regulatory and health technology assessment (HTA) perspective.WP1 will bring together multiple stakeholders, to ensure that it takes into account a wide range of perspectives.
-
Casmi Fellow - Adaptive LicensingCentre For The Advancement Of Sustainable Medical Innovation May 2012 - Apr 2017CASMI is the Centre for the Advancement of Sustainable Medical Innovation, a partnership between Oxford University and UCL, created to develop new models for medical innovation. The centre aims to address the issues that have lead to current failures in the translation of basic bioscience into affordable and widely adopted new treatments. Adaptive approaches to licensing aim to streamline the research, licensing and market access processes by involvement of all stakeholders including the sponsor, regulator, payers/providers and the research community. A drug-specific development plan is agreed that provides sufficient information on risk versus benefit to enable prompt authorization in a defined group of patients and/or treatment settings. This followed by monitoring of ‘real-life’ effectiveness and safety and leads to further license adaptation. AL may use existing regulatory pathways or explore novel methodologies.
-
Person AppointedUk Regulation Of Medicines Review Panel Jan 2009 - Apr 2017London, United KingdomThe Regulation of Medicines Review Panel is a permanent panel of individuals who are independent of the pharmaceutical industry, the licensing authority or its advisors. The panel carries out independent reviews of licensing authority decisions, performing the function of the ‘person appointed’ in the Medicines Act 1968 and subordinate legislation.
-
Editor, Skin GroupCochrane Collaboration 2005 - Oct 2012
-
Harkness Fellow In Healthcare Policy And PracticeThe Commonwealth Fund 2010 - 2011Tufts University/Center For Medical Technology Policy/MitThe Harkness Fellowships are a programme run by the Commonwealth Fund of New York City. They were established to reciprocate the Rhodes Scholarships and enable Fellows from several countries to spend time studying in the United States.A one year research fellowship in the United States focusing on the inter-relationship between comparative effectiveness research (health technology assessment) and innovation. An evaluation of policy solutions including adaptive licensing of pharmaceuticals and value-based insurance design.Mentors: Peter Neumann (Tufts University), Sean Tunis (CMTP), Ruth Faden (Johns Hopkins University), Alan Garber (Stanford University). -
Pharmacist Lead- Medicines ManagementUk Department Of Health Specialist Advisory Committee On Antimicrobial Resistance Jan 2006 - Dec 2007In 1969, the Swann Committee reported that there was a significant problem with regard to antimicrobial (mis)use in both human and veterinary practice and recommended that the UK Government establish a committee that should have overall responsibility for the whole field of antimicrobial use. This view was reiterated in 1997-8 by the House of Lords Science and Technology Committee, under the Chairmanship of Lord Soulsby of Swaffham Prior. In 2001 such a group, the Specialist Advisory Committee on Antimicrobial Resistance (SACAR), was finally launched. SACAR encompassed representatives from human and veterinary medicine and involved many branches of public health, pharmacy, nursing, bacteriology and virology. It met three times a year and has advised ministers and the Chief Medical Officer on current and emerging problems by providing expert advice to inform local and national policy on antimicrobial resistance.
Sarah Garner Skills
Sarah Garner Education Details
-
Health Technology Assessment -
Pharmacy
Frequently Asked Questions about Sarah Garner
What company does Sarah Garner work for?
Sarah Garner works for University College London
What is Sarah Garner's role at the current company?
Sarah Garner's current role is Honorary Professor.
What is Sarah Garner's email address?
Sarah Garner's email address is sa****@****.org.uk
What schools did Sarah Garner attend?
Sarah Garner attended University Of Nottingham, University Of Nottingham.
What skills is Sarah Garner known for?
Sarah Garner has skills like Policy, Hta, Healthcare, Clinical Research, Public Health, Health Economics, Healthcare Management, Research, Clinical Trials, Pharmaceutical Industry, Strategic Planning, Medical Devices.
Not the Sarah Garner you were looking for?
-
1homeretailgroup.com -
Sarah Garner
Chelmsford1prgx.com -
1city.ac.uk -
Sarah Garner
Hailsham
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial